GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, announced on October 26, 2026, that it has entered into an unsecured $1,000,000 Revolving Loan Agreement with Bowery Consulting Group Inc. The loan, dated October 23, 2026, carries a 12% annual interest rate and matures in 12 months. Advances under the facility are subject to the lender's approval, according to the press release.
The agreement's implications extend beyond financing: it triggered a significant board restructuring. On October 23, 2026, five directors—Randal Chase, Dean Kollintzas, Nicole Lemerond, Jayne Morgan, and John Spencer, Jr.—resigned. Simultaneously, Steven Brown, Tyler O’Brien, and Manpreet Uppal were appointed as directors, each nominated by the lender pursuant to the loan agreement. The board now comprises five directors, with the new appointees serving until the loan is repaid in full or they resign under the agreement's terms. The board determined that all new directors meet SEC and Nasdaq independence standards. O’Brien and Uppal will join the Audit Committee alongside Dr. Robert McNally.
This board overhaul, dictated by the lender, raises questions about governance and control. While the loan strengthens GeoVax's balance sheet, the lender's ability to appoint directors and the new directors' tenure tied to loan repayment could influence corporate strategy. CEO David A. Dodd framed the changes positively, stating, “Securing this financing is an important achievement for GeoVax, reinforcing our balance sheet and providing the working capital needed to support our operations.” He welcomed the new directors, citing their diverse experience, and thanked departing members. Dodd also emphasized the company's focus on advancing its GEO-MVA clinical program for mpox and smallpox, which is planned for a pivotal Phase 3 trial in late 2026.
The financing and board changes come as GeoVax pursues expedited development of GEO-MVA and its oncology candidate Gedeptin®. The revolving loan provides working capital but also introduces debt obligations and lender influence. The newly composed board will oversee these efforts, and further details will be disclosed in a Form 8-K filing with the SEC. For more information, visit www.geovax.com.
